Incyte Corporation (NASDAQ: INCY) — Q2 2023 Form 10-Q
Reporting period: Three and six months ended June 30, 2023; unaudited. Incyte is a biopharmaceutical company with commercial products and a drug-development pipeline. It reports one operating segment.
Key financial results
| Metric | Q2 2023 | Q2 2022 | Change |
|---|---|---|---|
| Total revenue | $954.6 million | $911.4 million | +4.7% |
| Operating income | $193.8 million | $254.4 million | -23.9% |
| Net income | $203.5 million | $161.4 million | +26.1% |
| Diluted EPS | $0.90 | $0.72 | +25.0% |
| Operating margin | 20.3% | 27.9% | Down 7.6 percentage points |
| Net margin | 21.3% | 17.7% | Up 3.6 percentage points |
For the first six months, revenue was $1.763 billion (+7.2% year over year), operating income was $218.6 million (-41.1%), and net income was $225.3 million (+13.0%). Diluted EPS was $1.00, compared with $0.89.
Revenue mix and operating trends
- Q2 product revenue was $827.0 million, up 24.6%; product royalties were $127.6 million, up 8.6%. No milestone or contract revenue was recorded, versus $130.0 million in Q2 2022.
- JAKAFI revenue was $682.4 million (+14.2%) and remained the largest source. OPZELURA revenue rose to $80.2 million from $16.6 million, supported by demand and expanded coverage. MINJUVI revenue included approximately $6.0 million of previously deferred French Early Access Program revenue. ZYNYZ contributed $0.6 million following its U.S. approval.
- Operating expenses increased: research and development was $400.8 million (+15.4%) and selling, general and administrative expense was $283.9 million (+12.1%). Management cited pipeline investment, increased staffing, and OPZELURA launch promotion.
- Operating income declined despite higher revenue, principally as the prior-year quarter included $130 million of milestone and contract revenue and 2023 expenses increased. Net income benefited from $41.8 million of unrealized gains on long-term investments, versus a $24.9 million loss a year earlier, and higher interest income.
Cash, liquidity and capital
- Cash and cash equivalents were $3.131 billion at June 30, 2023; marketable securities were $292.2 million and long-term investments were $170.3 million. Management reported $3.4 billion of cash, cash equivalents and marketable securities.
- Six-month operating cash flow was $200.9 million, down from $389.9 million. The filing attributes the decrease primarily to working-capital changes, including inventory growth and lower accounts payable.
- Six-month investing cash outflow was $36.0 million; financing cash inflow was $16.9 million. Cash, cash equivalents, restricted cash and investments increased $179.7 million during the period.
- Total liabilities were $1.468 billion and stockholders’ equity was $4.741 billion. The company had no borrowings outstanding under its $500 million revolving credit facility and stated it was in covenant compliance. Finance lease liabilities totaled $32.7 million.
- Management said operating cash flow, cash and investments, and facility availability should meet capital needs for the foreseeable future. No formal revenue or earnings guidance is provided in the supplied filing text.
Material developments, outlook and risks
- In March 2023, the FDA issued a complete response letter for once-daily ruxolitinib extended-release tablets, identifying additional requirements for approval; Incyte said it would work with the FDA on next steps.
- In early 2023, Incyte discontinued parsaclisib programs in myelofibrosis and warm hemolytic anemia and certain other early-stage programs. Two Phase III studies of ruxolitinib plus parsaclisib were stopped after interim analyses indicated they were unlikely to meet primary endpoints; the decision was not attributed to safety.
- The filing reports a contract dispute with Novartis: $310.3 million of accrued U.S. JAKAFI royalties was included in current liabilities at June 30, and payment depends on the dispute’s outcome.
- Incyte identified reliance on JAKAFI, pricing and reimbursement pressure, competition and possible generic entry, product safety and regulatory risks, clinical-development uncertainty, collaborator dependence, and limited-source manufacturing and supply as significant risks. Five customers together represented 35% of accounts receivable at quarter-end.
- Management disclosed that implementation of a new enterprise resource planning system began in Q2 and was expected to continue through Q3 2023. Disclosure controls were assessed as effective at the reasonable-assurance level.
- After quarter-end, the company and Syndax announced that the AGAVE-201 axatilimab trial met its primary endpoint; the filing reports a 74% response rate at the 0.3 mg/kg dose and notes 60% of responders at that dose remained in response at one year. This is a post-period development, not a Q2 financial result.
Most important facts for investors to verify
- Progress and potential financial resolution of the Novartis royalty dispute, including the $310.3 million accrued balance.
- Whether growth in JAKAFI and OPZELURA can offset the loss of prior-period milestone revenue and ongoing expense growth.
- FDA requirements and timing for the ruxolitinib XR application, and clinical and regulatory progress across late-stage programs.
- Product access, reimbursement, customer concentration, manufacturing capacity and supply continuity, particularly for JAKAFI.
- How much reported earnings reflect operating performance versus volatile unrealized investment gains and interest income.
- Working-capital trends, including inventory and accrued liabilities, and execution of the ERP system implementation.